Previous 10 | Next 10 |
Castle Biosciences, Inc. (CSTL) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Camilla Zuckero - Executive Director, Investor Relations & Corporate Communications Derek Maetzold - Founder, President & Chief Executive Officer Frank Stokes - Chief Financ...
Q2 2021 revenues of $22.8 million, compared to $12.7 million in Q2 2020 Q2 2021 total dermatology test report volume of 6,539 DecisionDx-Melanoma test reports increased 70%, compared to Q2 2020 Raising 2021 Revenue Guidance to $89-93 million from $80-83 million...
Oral presentations to highlight DecisionDx®-Melanoma and DecisionDx®-SCC Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that data on two of its sk...
Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced data presentations on two of its skin cancer gene expression profile tests at the DEF (Dermatology Education Foundation) ...
Castle Biosciences will sponsor Miles for Melanoma 5K events and annual galas across the U.S. Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced its continued c...
Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Canaccord G...
Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that it will release its financial results for the second quarter and six months ended June 30, 2021, after the close of ...
Data Presented at American Head & Neck Society (AHNS) 10th International Conference on Head and Neck Cancer Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announc...
New data demonstrate that the majority of NP/PAs who utilize DecisionDx-Melanoma would consider altering patient management for a thin (T1) tumor or Stage 1 melanoma that received a high-risk result Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that Kim Caple and Ellen Goldberg have been appointed to its board of directors, effective immediately. “We ar...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...